PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21709443-8	2011	METHODS: The cytotoxicity of topotecan after conventional or metronomic dosing was determined by examining cellular morphology, mitochondrial enzymatic activity (MTT), total cellular protein (SRB), annexin V and propidium iodine (PI) staining, cell cycle and western blot analysis in human prostate cancer cell lines (PC-3 and LNCaP) and the effects metronomic or continuous infusion on tumor growth in an in vivo tumor xenograft model.	Topotecan	29-38	annexin A5	Homo sapiens	198-207	
12811515-10	2003	Surprisingly, only topotecan, a topoisomerase I inhibitor, when used in combination with rTRAIL/Apo-2L led to significant apoptosis of DU-145 cells, as measured by caspase 8 activation, BID cleavage, and annexin V-FITC/PI staining.	Topotecan	19-28	annexin A5	Homo sapiens	204-213	
26536450-7	2015	RESULTS: A 48 hours exposure of human erythrocytes to topotecan significantly increased the percentage of annexin-V-binding cells and significantly decreased forward scatter.	Topotecan	54-63	annexin A5	Homo sapiens	106-115	
26536450-9	2015	The effect of topotecan on annexin-V-binding was significantly blunted, but not abolished by removal of extracellular Ca2+.	Topotecan	14-23	annexin A5	Homo sapiens	27-36